Literature DB >> 24333317

Present and future challanges in the treatment of haemophilia: a clinician's perspective.

Pier Mannuccio Mannucci1, Massimo Franchini2.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24333317      PMCID： PMC3853988          DOI： 10.2450/2013.012s

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  36 in total

1.  Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.

Authors:  G C White; F Rosendaal; L M Aledort; J M Lusher; C Rothschild; J Ingerslev
Journal:  Thromb Haemost       Date:  2001-03       Impact factor: 5.249

2.  The principal results of the International Immune Tolerance Study: a randomized dose comparison.

Authors:  Charles R M Hay; Donna M DiMichele
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

Review 3.  The hope and reality of long-acting hemophilia products.

Authors:  Steven W Pipe
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

4.  Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

Authors:  Amy D Shapiro; Margaret V Ragni; Leonard A Valentino; Nigel S Key; Neil C Josephson; Jerry S Powell; Gregory Cheng; Arthur R Thompson; Jaya Goyal; Karen L Tubridy; Robert T Peters; Jennifer A Dumont; Donald Euwart; Lian Li; Bengt Hallén; Peter Gozzi; Alan J Bitonti; Haiyan Jiang; Alvin Luk; Glenn F Pierce
Journal:  Blood       Date:  2011-11-22       Impact factor: 22.113

Review 5.  Modern haemophilia care.

Authors:  Erik Berntorp; Amy D Shapiro
Journal:  Lancet       Date:  2012-03-27       Impact factor: 79.321

Review 6.  How we choose factor VIII to treat hemophilia.

Authors:  Pier Mannuccio Mannucci; Maria Elisa Mancuso; Elena Santagostino
Journal:  Blood       Date:  2012-03-12       Impact factor: 22.113

7.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

Authors:  Jerry S Powell; Neil C Josephson; Doris Quon; Margaret V Ragni; Gregory Cheng; Ella Li; Haiyan Jiang; Lian Li; Jennifer A Dumont; Jaya Goyal; Xin Zhang; Jurg Sommer; Justin McCue; Margaret Barbetti; Alvin Luk; Glenn F Pierce
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113

8.  Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

Authors:  Elena Santagostino; Claude Negrier; Robert Klamroth; Andreas Tiede; Ingrid Pabinger-Fasching; Christine Voigt; Iris Jacobs; Massimo Morfini
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

Review 9.  Past, present and future of hemophilia: a narrative review.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Orphanet J Rare Dis       Date:  2012-05-02       Impact factor: 4.123

10.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

Authors:  Amit C Nathwani; Edward G D Tuddenham; Savita Rangarajan; Cecilia Rosales; Jenny McIntosh; David C Linch; Pratima Chowdary; Anne Riddell; Arnulfo Jaquilmac Pie; Chris Harrington; James O'Beirne; Keith Smith; John Pasi; Bertil Glader; Pradip Rustagi; Catherine Y C Ng; Mark A Kay; Junfang Zhou; Yunyu Spence; Christopher L Morton; James Allay; John Coleman; Susan Sleep; John M Cunningham; Deokumar Srivastava; Etiena Basner-Tschakarjan; Federico Mingozzi; Katherine A High; John T Gray; Ulrike M Reiss; Arthur W Nienhuis; Andrew M Davidoff
Journal:  N Engl J Med       Date:  2011-12-10       Impact factor: 176.079
View more
  13 in total

Review 1.  Non-factor replacement therapy for haemophilia: a current update.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2018-02-14       Impact factor: 3.443

2.  Non-replacement therapy for haemophilia treatment: fetching the east by the west.

Authors:  Marco Marietta; Mario Luppi
Journal:  Blood Transfus       Date:  2018-03-02       Impact factor: 3.443

3.  The Italian institutional accreditation model for Haemophilia Centres.

Authors:  Gabriele Calizzani; Fabio Candura; Ivana Menichini; Romano Arcieri; Giancarlo Castaman; Alessandro Lamanna; Maria R Tamburrini; Antonio Fortino; Monica Lanzoni; Samantha Profili; Simonetta Pupella; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

4.  Definition of an organisational model for the prevention and reduction of health and social impacts of inherited bleeding disorders.

Authors:  Gabriele Calizzani; Ivana Menichini; Fabio Candura; Monica Lanzoni; Samantha Profili; Maria Rita Tamburrini; Antonio Fortino; Stefania Vaglio; Giuseppe Marano; Giuseppina Facco; Emily Oliovecchio; Massimo Franchini; Antonio Coppola; Romano Arcieri; Cinzia Bon; Mario Saia; Sabina Nuti; Massimo Morfini; Giancarlo M Liumbruno; Giovanni Di Minno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

5.  Emicizumab for the treatment of haemophilia A: a narrative review.

Authors:  Massimo Franchini; Giuseppe Marano; Ilaria Pati; Fabio Candura; Samantha Profili; Eva Veropalumbo; Francesca Masiello; Liviana Catalano; Vanessa Piccinini; Stefania Vaglio; Simonetta Pupella; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2019-05       Impact factor: 3.443

Review 6.  Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia

Authors:  Richard S Blumberg; David Lillicrap
Journal:  Blood       Date:  2018-03-27       Impact factor: 22.113

Review 7.  Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia.

Authors:  Albert Farrugia; Giancarlo M Liumbruno; Fabio Candura; Samantha Profili; Josephine Cassar
Journal:  Blood Transfus       Date:  2018-09-03       Impact factor: 3.443

8.  Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.

Authors:  K John Pasi; Toshko Lissitchkov; Vasily Mamonov; Tim Mant; Margarita Timofeeva; Catherine Bagot; Pratima Chowdary; Pencho Georgiev; Liana Gercheva-Kyuchukova; Kate Madigan; Huy Van Nguyen; Qifeng Yu; Baisong Mei; Craig C Benson; Margaret V Ragni
Journal:  J Thromb Haemost       Date:  2021-05-18       Impact factor: 5.824

Review 9.  Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.

Authors:  Lindsey A George; Rodney M Camire
Journal:  J Blood Med       Date:  2015-04-24

Review 10.  Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review.

Authors:  Jing Sun; Xuan Zhou; Nan Hu
Journal:  Orphanet J Rare Dis       Date:  2021-06-26       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.